.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Advancing Role of Immunotherapy in Multiple Myeloma

EP. 1: Rationale for Immunotherapy in Multiple Myeloma

March 29th 2016

EP. 2: Monoclonal Antibody Therapy in Myeloma

March 29th 2016

EP. 3: Safety and Efficacy of Daratumumab in Multiple Myeloma

March 29th 2016

EP. 4: Safety and Efficacy of Elotuzumab in Multiple Myeloma

March 29th 2016

EP. 5: Practical Advice on the Treatment of Multiple Myeloma

March 29th 2016

EP. 6: Goals of Therapy in Multiple Myeloma

March 29th 2016

EP. 7: Immunotherapy Patient Selection in Myeloma

March 29th 2016

EP. 8: Antibodies in Combination Therapy for Myeloma

March 29th 2016

EP. 9: On the Horizon for Multiple Myeloma

March 29th 2016

EP. 10: The Future of Immunotherapy in Myeloma

March 29th 2016